Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Rheumatology Reports
Erschienen in: Current Rheumatology Reports 12/2021

01.12.2021 | Crystal Arthritis (M Pillinger and M Toprover, Section Editors)

Hyperuricemia, Gout, and the Brain—an Update

verfasst von: Augustin Latourte, Julien Dumurgier, Claire Paquet, Pascal Richette

Erschienen in: Current Rheumatology Reports | Ausgabe 12/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review aims to summarize recent evidence regarding the complex relationship between uric acid (UA), gout, and brain diseases.

Recent Findings

Observational studies have suggested that patients with hyperuricemia or gout might have a decreased risk of neurodegenerative diseases. Conversely, they may be at increased risk of cerebrovascular disease. Mendelian randomization (MR) studies use a genetic score as an instrumental variable to address the causality of the association between a risk factor (here, UA or gout) and an outcome. So far, MR analyses do not support a causal relationship of UA or gout with Alzheimer’s disease and dementia, and of UA with Parkinson’s disease or stroke.

Summary

Observation studies indicate a U-shaped association between UA and brain diseases, but MR studies do not support that this association is causal. Further studies should address the causal role of gout as well as the impact of urate-lowering therapy on these outcomes.
Literatur
1.
Richette P, Perez-Ruiz F, Doherty M, Jansen TL, Nuki G, Pascual E, et al. Improving cardiovascular and renal outcomes in gout: what should we target? Nat Rev Rheumatol. 2014;10(11):654–61.PubMedCrossRef
2.
Bardin T. Hyperuricemia starts at 360 micromoles (6 mg/dL). Joint Bone Spine. 2015;82(3):141–3.PubMedCrossRef
3.
FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Rheumatol. 2020;72(6):879–95.PubMedCrossRef
4.
Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29–42.PubMedCrossRef
5.
Kratzer JT, Lanaspa MA, Murphy MN, Cicerchi C, Graves CL, Tipton PA, et al. Evolutionary history and metabolic insights of ancient mammalian uricases. Proc Natl Acad Sci U S A. 2014;111(10):3763–8.PubMedPubMedCentralCrossRef
6.
Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A. 1981;78(11):6858–62.PubMedPubMedCentralCrossRef
7.
De Giorgi A, Fabbian F, Pala M, Tiseo R, Parisi C, Misurati E, et al. Uric acid: friend or foe? Uric acid and cognitive function “Gout kills more wise men than simple.” Eur Rev Med Pharmacol Sci. 2015;19(4):640–6.PubMed
8.
Radi E, Formichi P, Battisti C, Federico A. Apoptosis and oxidative stress in neurodegenerative diseases. J Alzheimers Dis. 2014;42(Suppl 3):S125–52.PubMedCrossRef
9.
Yu W, Cheng JD. Uric Acid and Cardiovascular disease: an update from molecular mechanism to clinical perspective. Front Pharmacol. 2020;11:582680.
10.
11.
Hershfield MS, Roberts LJ 2nd, Ganson NJ, Kelly SJ, Santisteban I, Scarlett E, et al. Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo. Proc Natl Acad Sci U S A. 2010;107(32):14351–6.PubMedPubMedCentralCrossRef
12.
Furuhashi M, Matsumoto M, Tanaka M, Moniwa N, Murase T, Nakamura T, et al. Plasma xanthine oxidoreductase activity as a novel biomarker of metabolic disorders in a general population. Circ J. 2018;82(7):1892–9.PubMedCrossRef
13.
Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006;58(1):87–114.PubMedCrossRef
14.
Dalbeth N, Choi HK, Joosten LAB, Khanna PP, Matsuo H, Perez-Ruiz F, et al. Gout Nat Rev Dis Primers. 2019;5(1):69.PubMedCrossRef
15.
Joosten LAB, Crisan TO, Bjornstad P, Johnson RJ. Asymptomatic hyperuricaemia: a silent activator of the innate immune system. Nat Rev Rheumatol. 2020;16(2):75–86.PubMedCrossRef
16.
Crisan TO, Cleophas MC, Oosting M, Lemmers H, Toenhake-Dijkstra H, Netea MG, et al. Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra. Ann Rheum Dis. 2016;75(4):755–62.PubMedCrossRef
17.
Crisan TO, Cleophas MCP, Novakovic B, Erler K, van de Veerdonk FL, Stunnenberg HG, et al. Uric acid priming in human monocytes is driven by the AKT-PRAS40 autophagy pathway. Proc Natl Acad Sci U S A. 2017;114(21):5485–90.PubMedPubMedCentralCrossRef
18.
Braga TT, Forni MF, Correa-Costa M, Ramos RN, Barbuto JA, Branco P, et al. Soluble uric acid activates the NLRP3 inflammasome. Sci Rep. 2017;7:39884.PubMedPubMedCentralCrossRef
19.
Jin Y, Fu J. Novel insights into the NLRP 3 inflammasome in atherosclerosis. J Am Heart Assoc. 2019;8(12):e012219.
20.
Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–31.PubMedCrossRef
21.
Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497–505.PubMedCrossRef
22.
Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol. 2008;9(8):857–65.PubMedPubMedCentralCrossRef
23.
Ising C, Venegas C, Zhang S, Scheiblich H, Schmidt SV, Vieira-Saecker A, et al. NLRP3 inflammasome activation drives tau pathology. Nature. 2019;575(7784):669–73.PubMedPubMedCentralCrossRef
24.
Trudler D, Nazor KL, Eisele YS, Grabauskas T, Dolatabadi N, Parker J, et al. Soluble alpha-synuclein-antibody complexes activate the NLRP3 inflammasome in hiPSC-derived microglia. Proc Natl Acad Sci U S A. 2021;118(15).
25.
Ising C, Heneka MT. Functional and structural damage of neurons by innate immune mechanisms during neurodegeneration. Cell Death Dis. 2018;9(2):120.PubMedPubMedCentralCrossRef
26.
McFarland NR, Burdett T, Desjardins CA, Frosch MP, Schwarzschild MA. Postmortem brain levels of urate and precursors in Parkinson’s disease and related disorders. Neurodegener Dis. 2013;12(4):189–98.PubMedCrossRef
27.
Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol. 2009;66(12):1460–8.PubMedPubMedCentralCrossRef
28.
29.
Chen X, Guo X, Huang R, Chen Y, Zheng Z, Shang H. Serum uric acid levels in patients with Alzheimer’s disease: a meta-analysis. PLoS One. 2014;9(4):e94084.
30.
Khan AA, Quinn TJ, Hewitt J, Fan Y, Dawson J. Serum uric acid level and association with cognitive impairment and dementia: systematic review and meta-analysis. Age (Dordr). 2016;38(1):16.CrossRef
31.
Euser SM, Hofman A, Westendorp RG, Breteler MM. Serum uric acid and cognitive function and dementia. Brain. 2009;132(Pt 2):377–82.PubMed
32.
Latourte A, Soumare A, Bardin T, Perez-Ruiz F, Debette S, Richette P. Uric acid and incident dementia over 12 years of follow-up: a population-based cohort study. Ann Rheum Dis. 2018;77(3):328–35.PubMedCrossRef
33.
Scheepers L, Jacobsson LTH, Kern S, Johansson L, Dehlin M, Skoog I. Urate and risk of Alzheimer’s disease and vascular dementia: a population-based study. Alzheimers Dement. 2019;15(6):754–63.PubMedCrossRef
34.
Cao Z, Xu C, Yang H, Li S, Xu F, Zhang Y, et al. Associations of BMI and serum urate with developing dementia: a prospective cohort study. J Clin Endocrinol Metab. 2020;105(12).
35.
Ye BS, Lee WW, Ham JH, Lee JJ, Lee PH, Sohn YH, et al. Does serum uric acid act as a modulator of cerebrospinal fluid Alzheimer’s disease biomarker related cognitive decline? Eur J Neurol. 2016;23(5):948–57.PubMedCrossRef
36.
Li LL, Ma YH, Bi YL, Sun FR, Hu H, Hou XH, et al. Serum uric acid may aggravate Alzheimer’s disease risk by affecting amyloidosis in cognitively intact older adults: the CABLE study. J Alzheimers Dis. 2021;81(1):389–401.PubMedCrossRef
37.
Desideri G, Gentile R, Antonosante A, Benedetti E, Grassi D, Cristiano L, et al. Uric acid amplifies Abeta amyloid effects involved in the cognitive dysfunction/dementia: evidences from an experimental model in vitro. J Cell Physiol. 2017;232(5):1069–78.PubMedCrossRef
38.
Efstathiadou A, Gill D, McGrane F, Quinn T, Dawson J. Genetically determined uric acid and the risk of cardiovascular and neurovascular diseases: a Mendelian randomization study of outcomes investigated in randomized trials. J Am Heart Assoc. 2019;8(17):e012738.
39.
Wang Z, Meng L, Shen L, Ji HF. Impact of modifiable risk factors on Alzheimer’s disease: a two-sample Mendelian randomization study. Neurobiol Aging. 2020;91(167):e11–9.
40.
Yuan H, Yang W. Genetically Determined serum uric acid and Alzheimer’s disease risk. J Alzheimers Dis. 2018;65(4):1259–65.PubMedCrossRef
41.
Shen C, Guo Y, Luo W, Lin C, Ding M. Serum urate and the risk of Parkinson’s disease: results from a meta-analysis. Can J Neurol Sci. 2013;40(1):73–9.PubMedCrossRef
42.
Wen M, Zhou B, Chen YH, Ma ZL, Gou Y, Zhang CL, et al. Serum uric acid levels in patients with Parkinson’s disease: a meta-analysis. PLoS One. 2017;12(3):e0173731.
43.
Moccia M, Picillo M, Erro R, Vitale C, Longo K, Amboni M, et al. Presence and progression of non-motor symptoms in relation to uric acid in de novo Parkinson’s disease. Eur J Neurol. 2015;22(1):93–8.PubMedCrossRef
44.
Huang X, Ng SY, Chia NS, Acharyya S, Setiawan F, Lu ZH, et al. Serum uric acid level and its association with motor subtypes and non-motor symptoms in early Parkinson’s disease: PALS study. Parkinsonism Relat Disord. 2018;55:50–4.PubMedCrossRef
45.
Oh YS, Kim JS, Yoo SW, Hwang EJ, Lyoo CH, Lee KS. Gender difference in the effect of uric acid on striatal dopamine in early Parkinson’s disease. Eur J Neurol. 2020;27(2):258–64.PubMedCrossRef
46.
Parkinson Study Group S-PDI, Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014;71(2):141–50.
47.
Schwarzschild MA, Macklin EA, Bakshi R, Battacharyya S, Logan R, Espay AJ, et al. Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial. Neurology. 2019;93(14):e1328–38.PubMedPubMedCentralCrossRef
48.
Simon KC, Eberly S, Gao X, Oakes D, Tanner CM, Shoulson I, et al. Mendelian randomization of serum urate and Parkinson disease progression. Ann Neurol. 2014;76(6):862–8.PubMedPubMedCentralCrossRef
49.
Kia DA, Noyce AJ, White J, Speed D, Nicolas A, collaborators I, et al. Mendelian randomization study shows no causal relationship between circulating urate levels and Parkinson’s disease. Ann Neurol. 2018;84(2):191–9.
50.
Kobylecki CJ, Nordestgaard BG, Afzal S. Plasma urate and risk of Parkinson’s disease: a Mendelian randomization study. Ann Neurol. 2018;84(2):178–90.PubMedCrossRef
51.
Cortese M, Riise T, Engeland A, Ascherio A, Bjornevik K. Urate and the risk of Parkinson’s disease in men and women. Parkinsonism Relat Disord. 2018;52:76–82.PubMedCrossRef
52.
Du L, Ma J, Zhang X. Higher serum uric acid may contribute to cerebral infarction in patients with type 2 diabetes mellitus: a meta-analysis. J Mol Neurosci. 2017;61(1):25–31.PubMedCrossRef
53.
Zhong C, Zhong X, Xu T, Xu T, Zhang Y. Sex-specific relationship between serum uric acid and risk of stroke: a dose-response meta-analysis of prospective studies. J Am Heart Assoc. 2017;6(4).
54.
Zhou Z, Liang Y, Lin J, Zhang X, Qu H, Xu J, et al. Serum uric acid concentrations and risk of intracerebral hemorrhage: a systematic review and meta-analysis. Atherosclerosis. 2018;275:352–8.PubMedCrossRef
55.
Huang J, Hu D, Wang Y, Zhang D, Qu Y. Dose-response relationship of serum uric acid levels with risk of stroke mortality. Atherosclerosis. 2014;234(1):1–3.PubMedCrossRef
56.
Keenan T, Zhao W, Rasheed A, Ho WK, Malik R, Felix JF, et al. Causal assessment of serum urate levels in cardiometabolic diseases through a Mendelian randomization study. J Am Coll Cardiol. 2016;67(4):407–16.PubMedPubMedCentralCrossRef
57.
Lei Z, Cai J, Hong H, Wang Y. Serum uric acid level and outcome of patients with ischemic stroke: a systematic review and meta-analysis. Neurologist. 2019;24(4):121–31.PubMedCrossRef
58.
Wang Z, Lin Y, Liu Y, Chen Y, Wang B, Li C, et al. Serum uric acid levels and outcomes after acute ischemic stroke. Mol Neurobiol. 2016;53(3):1753–9.PubMedCrossRef
59.
Chamorro A, Amaro S, Castellanos M, Segura T, Arenillas J, Marti-Fabregas J, et al. Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised, double-blind phase 2b/3 trial. Lancet Neurol. 2014;13(5):453–60.PubMedCrossRef
60.
Llull L, Laredo C, Renu A, Perez B, Vila E, Obach V, et al. Uric acid therapy improves clinical outcome in women with acute ischemic stroke. Stroke. 2015;46(8):2162–7.PubMedCrossRef
61.
Amaro S, Laredo C, Renu A, Llull L, Rudilosso S, Obach V, et al. Uric acid therapy prevents early ischemic stroke progression: a tertiary analysis of the URICO-ICTUS trial (efficacy study of combined treatment with uric acid and r-tPA in acute ischemic stroke). Stroke. 2016;47(11):2874–6.PubMedCrossRef
62.
Chamorro A, Amaro S, Castellanos M, Gomis M, Urra X, Blasco J, et al. Uric acid therapy improves the outcomes of stroke patients treated with intravenous tissue plasminogen activator and mechanical thrombectomy. Int J Stroke. 2017;12(4):377–82.PubMedCrossRef
63.
Crosta F, Occhiuzzi U, Passalacqua G, Occhiuzzi E, Cimini A, Grassi D, et al. Association between the serum uric acid levels and lacunar infarcts in the elderly. J Mol Neurosci. 2018;65(3):385–90.PubMedCrossRef
64.
Han SW, Song TJ, Bushnell CD, Lee SS, Kim SH, Lee JH, et al. Serum uric acid is associated with cerebral white matter hyperintensities in patients with acute lacunar infarction. J Neuroimaging. 2016;26(3):351–4.PubMedCrossRef
65.
Jeong SM, Yoo TG, Nam YS, Kim SH, Lee JE, Kim S, et al. Sex-dependent effects of uric acid on cerebral microbleed: a cross-sectional study in the general population. Eur J Neurol. 2017;24(10):1300–6.PubMedCrossRef
66.
Ryu WS, Kim CK, Kim BJ, Lee SH. Serum uric acid levels and cerebral microbleeds in patients with acute ischemic stroke. PLoS One. 2013;8(1):e55210.
67.
Schretlen DJ, Inscore AB, Vannorsdall TD, Kraut M, Pearlson GD, Gordon B, et al. Serum uric acid and brain ischemia in normal elderly adults. Neurology. 2007;69(14):1418–23.PubMedCrossRef
68.
Sun MJ, Li BH, Long CY, Wang YQ, Zhou Y, Liu Y, et al. Association between serum uric acid levels and cerebral white matter lesions in Chinese individuals. Int J Neurosci. 2016;126(12):1103–11.PubMedCrossRef
69.
70.
Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med. 2017;15(1):123.PubMedPubMedCentralCrossRef
71.
Hong JY, Lan TY, Tang GJ, Tang CH, Chen TJ, Lin HY. Gout and the risk of dementia: a nationwide population-based cohort study. Arthritis Res Ther. 2015;17:139.PubMedPubMedCentralCrossRef
72.
Lu N, Dubreuil M, Zhang Y, Neogi T, Rai SK, Ascherio A, et al. Gout and the risk of Alzheimer’s disease: a population-based. BMI-matched cohort study Ann Rheum Dis. 2016;75(3):547–51.PubMedCrossRef
73.
Vargas-Santos AB, Neogi T, da Rocha C-P, Kapetanovic MC, Turkiewicz A. Cause-specific mortality in gout: novel findings of elevated risk of non-cardiovascular-related deaths. Arthritis Rheumatol. 2019;71(11):1935–42.PubMedPubMedCentralCrossRef
74.
Singh JA, Cleveland JD. Use of urate-lowering therapies is not associated with an increase in the risk of incident dementia in older adults. Ann Rheum Dis. 2018;77(8):1243–5.PubMed
75.
Lee YH. Gout and the risk of Alzheimer’s disease: a Mendelian randomization study. Int J Rheum Dis. 2019;22(6):1046–51.PubMed
76.
Ungprasert P, Srivali N, Thongprayoon C. Gout is not associated with a lower risk of Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2015;21(10):1238–42.PubMedCrossRef
77.
Singh JA, Cleveland JD. Gout and the risk of Parkinson’s disease in older adults: a study of U.S. Medicare data. BMC Neurol. 2019;19(1):4.
78.
Hu LY, Yang AC, Lee SC, You ZH, Tsai SJ, Hu CK, et al. Risk of Parkinson’s disease following gout: a population-based retrospective cohort study in Taiwan. BMC Neurol. 2020;20(1):338.PubMedPubMedCentralCrossRef
79.
Seminog OO, Goldacre MJ. Gout as a risk factor for myocardial infarction and stroke in England: evidence from record linkage studies. Rheumatology (Oxford). 2013;52(12):2251–9.CrossRef
80.
Clarson LE, Hider SL, Belcher J, Heneghan C, Roddy E, Mallen CD. Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK clinical practice research datalink. Ann Rheum Dis. 2015;74(4):642–7.PubMedCrossRef
81.
Singh JA, Ramachandaran R, Yu S, Yang S, Xie F, Yun H, et al. Is gout a risk equivalent to diabetes for stroke and myocardial infarction? A retrospective claims database study. Arthritis Res Ther. 2017;19(1):228.PubMedPubMedCentralCrossRef
82.
Yen FS, Hsu CC, Li HL, Wei JC, Hwu CM. Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout. PLoS One. 2020;15(6):e0234909.
83.
Sebesta I, Stiburkova B, Bartl J, Ichida K, Hosoyamada M, Taylor J, et al. Diagnostic tests for primary renal hypouricemia. Nucleosides Nucleotides Nucleic Acids. 2011;30(12):1112–6.PubMedCrossRef
84.
Fujinaga S, Ito A, Nakagawa M, Watanabe T, Ohtomo Y, Shimizu T. Posterior reversible encephalopathy syndrome with exercise-induced acute kidney injury in renal hypouricemia type 1. Eur J Pediatr. 2013;172(11):1557–60.PubMedCrossRef
85.
Mou LJ, Jiang LP, Hu Y. A novel homozygous GLUT9 mutation cause recurrent exercise-induced acute renal failure and posterior reversible encephalopathy syndrome. J Nephrol. 2015;28(3):387–92.PubMedCrossRef
86.
Shima Y, Nozu K, Nozu Y, Togawa H, Kaito H, Matsuo M, et al. Recurrent EIARF and PRES with severe renal hypouricemia by compound heterozygous SLC2A9 mutation. Pediatrics. 2011;127(6):e1621–5.PubMedCrossRef
Metadaten
Titel
Hyperuricemia, Gout, and the Brain—an Update
verfasst von
Augustin Latourte
Julien Dumurgier
Claire Paquet
Pascal Richette
Publikationsdatum
01.12.2021
Verlag
Springer US
Erschienen in
Current Rheumatology Reports / Ausgabe 12/2021
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-021-01050-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Metformin rückt in den Hintergrund

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

24.04.2024 | DGIM 2024 | Nachrichten

Bei Senioren mit Prostatakarzinom auf Anämie achten!
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise